p53 protein aggregation promotes platinum resistance in ovarian cancer

Oncogene

Volumn 34, Issue 27, 2015, Pages 3605-3616

  Yang Hartwich, Y ^a   Soteras, M G ^a   Lin, Z P ^a   Holmberg, J ^a   Sumi, N ^a   Craveiro, V ^a   Liang, M ^a   Romanoff, E ^a   Bingham, J ^a   Garofalo, F ^a   Alvero, A ^a   Mor, G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CARBOPLATIN; CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FAS ANTIGEN; PROTEIN BAX; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE; PROTEIN AGGREGATE; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL DEATH; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DNA METHYLATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; PROTEIN AGGREGATION; TRANSACTIVATION; TRANSIENT TRANSFECTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; ANIMAL; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROTEINOSIS; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; MUTATION; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84942673457     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.296     Document Type: Article

References (58)

1. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-177
2. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
3. UMD TP53 mutation database. http://p53.fr/.
4. IARC TP53 Database. http://www.iarc.fr/p53/Index.html.
5. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012;26:1268-1286.
6. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992;89:7262-7266.
7. Tominaga O, Hamelin R, Trouvat V, Salmon RJ, Lesec G, Thomas G et al. Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene 1993;8:2653-2658.
8. Houben R, Hesbacher S, Schmid CP, Kauczok CS, Flohr U, Haferkamp S et al. High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS ONE 2011;6:e22096.
9. Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK et al. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol 2013;130:565-569.
10. Silva JL, Rangel LP, Costa DC, Cordeiro Y, De Moura Gallo CV. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor. Biosci Rep 2013;33:593-603.
11. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011;7:285-295.
12. Ano Bom AP, Rangel LP, Costa DC, de Oliveira GA, Sanches D, Braga CA et al. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem 2012;287:28152-28162.
13. Levy CB, Stumbo AC, Ano Bom AP, Portari EA, Cordeiro Y, Silva JL et al. Colocalization of mutant p53 and amyloid-like protein aggregates in breast tumors. Int J Biochem Cell Biol 2011;43:60-64.
14. Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) 2003;81:678-699.
15. Higashimoto Y, Asanomi Y, Takakusagi S, Lewis MS, Uosaki K, Durell SR et al. Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry 2006;45:1608-1619.
16. Ishimaru D, Andrade LR, Teixeira LS, Quesado PA, Maiolino LM, Lopez PM et al. Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry 2003;42:9022-9027.
17. Rigacci S, Bucciantini M, Relini A, Pesce A, Gliozzi A, Berti A et al. The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys J 2008;94:3635-3646.
18. Butler JS, Loh SN. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry 2003;42:2396-2403.
19. Ishimaru D, Lima LM, Maia LF, Lopez PM, Ano Bom AP, Valente AP et al. Reversible aggregation plays a crucial role on the folding landscape of p53 core domain. Biophys J 2004;87:2691-2700.
20. Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 2011;144:67-78.
21. Forget KJ, Tremblay G, Roucou X p53 aggregates penetrate cells and induce the co-aggregation of intracellular p53. PLoS ONE 2013;8:e69242.
22. Lasagna-Reeves CA, Clos AL, Castillo-Carranza D, Sengupta U, Guerrero-Munoz M, Kelly B et al. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. Biochem Biophys Res Commun 2013;430:963-968.
23. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
24. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117(Pt 16):3539-3545.
25. Shih Ie M, Davidson B. Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol 2009;5:1641-1657.
26. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a subpopulation of stem cell-like cells in ovarian cancer. Oncogene 2010;29:2153-2159.
27. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011;10:325-335.
28. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2012;18:869-881.
29. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009;8:158-166.
30. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009;27:2405-2413.
31. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I et al. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene 2008;27:4712-4723.
32. Craveiro V, Yang-Hartwich Y, Holmberg JC, Sumi NJ, Pizzonia J, Griffin B et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med 2013;2:751-762.
33. Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 2010;9:237-248.
34. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-734.
35. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-723.
36. Tao W, Levine AJ. P19 (ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 1999;96:6937-6941.
37. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20-26.
38. Iwakuma T, Lozano G. MDM2 an introduction. Mol Cancer Res 2003;1:993-1000.
39. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005;5:27-41.
40. Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 2010;1804:1405-1412.
41. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007;2:18.
42. Zheng S, Chen P, McMillan A, Lafuente A, Lafuente MJ, Ballesta A et al. Correlations of partial and extensive methylation at the p14 (ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis 2000;21:2057-2064.
43. Ciechanover A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 2006;66(2 Suppl 1):S7-19.
44. Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci 2010;13:805-811.
45. Kraiss S, Spiess S, Reihsaus E, Montenarh M. Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation. Exp Cell Res 1991;192:157-164.
46. Wilcken R, Wang G, Boeckler FM, Fersht AR. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc Natl Acad Sci USA 2012;109:13584-13589.
47. Silva JL, Gallo CV, Costa DC, Rangel LP. Prion-like aggregation of mutant p53 in cancer. Trends Biochem Sci 2014;39:260-267.
48. Albor A, Kaku S, Kulesz-Martin M. Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants. Cancer Res 1998;58:2091-2094.
49. Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 2001;276:40583-40590.
50. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc 2006;1:241-245.
51. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M et al. Phenoxodiol - an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003;22:2611-2620.
52. Kayed R, Glabe CG. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol 2006;413:326-344.
53. Szybka M, Zakrzewska M, Rieske P, Pasz-Walczak G, Kulczycka-Wojdala D, Zawlik I et al. cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer. BMC Cancer 2009;9:278.
54. Wells J, Farnham PJ. Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. Methods 2002;26:48-56.
55. Klump B, Hsieh CJ, Dette S, Holzmann K, Kiebetalich R, Jung M et al. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin Cancer Res 2003;9:1773-1778.
56. Erica Golemis PDA (ed) Protein-Protein Interactions: A Molecular Cloning Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2002.
57. Wu TL. Two-dimensional difference gel electrophoresis. Methods Mol Biol 2006;328:71-95.
58. Dieguez-Acuna F, Kodama S, Okubo Y, Paz AC, Gygi SP, Faustman DL. Proteomics identifies multipotent and low oncogenic risk stem cells of the spleen. Int J Biochem Cell Biol 2010;42:1651-1660.